Randomized Phase II Trial Comparing Sequential First-line Sunitinib and Second-line Avelumab vs First-line Avelumab and Second-line Sunitinib for Metastatic Renal Cell Carcinoma: SUAVE Trial. Hoosier Cancer Research Network GU15-223
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Avelumab (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SUAVE Trial
- 31 Aug 2018 Biomarkers information updated
- 20 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
- 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.